CRNX
Crinetics Pharmaceuticals, Inc.
Key Financials
Net Income
$-465317000
↓ 55.9%
EPS (Diluted)
$-4.95
↓ 34.1%
Revenue
$7.7M
↑ 640.7%
Operating Income
$-516769000
↓ 52.5%
Total Assets
$1.1B
↓ 21.5%
Total Liabilities
$134.2M
↑ 22.2%
Cash & Equivalents
$101.5M
↓ 61.6%
Shareholders' Equity
$992.1M
↓ 25.1%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 15-12G | 9/11/2026 | View on SEC |
| 4 | 9/1/2026 | View on SEC |
| 4 | 9/1/2026 | View on SEC |
| 4 | 9/1/2026 | View on SEC |
| 4 | 9/1/2026 | View on SEC |
| 4 | 9/1/2026 | View on SEC |
| 4 | 9/1/2026 | View on SEC |
| 4 | 9/1/2026 | View on SEC |
| 4 | 9/1/2026 | View on SEC |
| 4 | 9/1/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | CRNX |
| Company Name | Crinetics Pharmaceuticals, Inc. |
| CIK | 1658247 |
| Sector | Pharmaceutical Preparations |
| Industry | Large accelerated filer |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 858-450-6464 |